News

In our continuing series with members of the Peggy Lillis Foundation, here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.

Several trial participants experienced concerning hepatobiliary events.

The interim analysis of its phase 3 study shows the company’s mRNA-1010 vaccine was efficacious against all 4 A and B influenza strains.

The federal agency’s Advisory Committee on Immunization Practices (ACIP) recommendation was to authorize and approve the updated 2023-2024 (monovalent, XBB containing) COVID-19 vaccines for persons 6 months of age and older.

Misinformation created unnecessary hospitalizations and mortality and demonstrated the chasm in public health communication.

The agency specified which age groups the vaccine is approved for and which are authorized to use them, paving the way for fall vaccinations to take place.

This new program from the federal agency can be viewed as a useful starting point for the development and assessment tool for sepsis programs with more granularity required.

The federal agency’s reports shows decreases in both hepatitis A and B, but hepatitis C saw a significant increase during 2021. However, the investigators note the pandemic may have impacted statistics and progress towards goals.

Learn more about how hospitalizations due to alcohol-associated hepatitis increased during the pandemic; the next installment in our ongoing RSV series; developing a product for a potential functional cure of hepatitis B; and an investigational vaccine being studied in a challenge trial for norovirus.

The investigational vaccine was studied in a challenge trial and has a novel modality in that it is delivered as a monovalent oral tablet.

Patient advocate Ella Balasa has been living with cystic fibrosis her whole life. She experienced a multidrug resistant infection in 2019 and is speaking about her personal experiences at the World AMR Congress reminding people about the need to improve the antibiotic development paradigm.

Biotech company is developing a product for a potential functional cure of the virus.

Due to increased RSV activity in the southeast United States, the CDC has issued an official Health Alert Network Health Advisory. The federal agency recommends clinicians prepare to implement recently FDA-approved prevention methods.

The Escherichia coli O157:H7 strain is linked to leafy greens–associated outbreaks over a multi-year period.

The company says its vaccine protects against the BA286 strain.

The formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) is a once-daily treatment for children living with HIV and meant to reduce pill burden.

In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.

Investigators found that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

From baby formula to ground beef to Trader Joe’s tamales, here are some recent foods to be aware of for recalls and warnings.

The European Medicines Agency (EMA) based its decision on preclinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates an improved response against multiple XBB-related sublineages, including XBB15, XBB116, XBB23, and EG51.

Learn more about an investigational antibiotic; a new series on the RSV pipeline and recently approved products; a review of an older antibiotic for a specific STI treatment; and a patient advocate's experience with C diff.

A new study found a higher risk of CDI associated with clindamycin and lower risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.

The CDC reports the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.

In preclinical studies, the antimicrobial, clovibactin, was shown to have susceptibility against a broad spectrum of pathogens and also worked against a specific bacteria in 2 animal studies.

If approved, the investigational vaccine would be available to people 18 years and older.

This is part of an occasional series with members of the Peggy Lillis Foundation. Here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.

Associated with excessive alcohol use, cirrhosis is one condition that can affect the pediatric population in the absence of alcohol.